AIM-listed AI specialist IXICO (LON:IXI) watched its share price climb by 15.32% to 104.37p (as of 13:40 GMT) after it announced a partnership with Microsoft. The collaboration will combine IXICO’s analytics and neurological expertise with Microsoft’s cloud platform to support clinical trials for conditions including Alzheimer’s and Huntingdon’s diseases.
CEO Giulio Cerroni commented: “The partnership with Microsoft ensures we remain at the forefront of data analytics required by our global pharmaceutical clients, to provide new and valuable insights to reduce both the high cost of drug development and the time to market for urgently needed drugs across a wide range of neurological diseases. We are excited to work with Microsoft on our clinical trial data platform, as well as AI analytics framework, as we look to scale our business and increase our value to both current and prospective clients“.